A small prospective single-arm study from Italy investigated 32 patients aged 70 years and older with GBM assigned to 60 Gy of RT with concurrent and adjuvant TMZ, finding median overall survival to be 10.6 months, which compares favorably with RT alone, though this had no comparator arm.
This study had no comparator group of patients with II.
All previous studies had no comparator group of patients with II.
Typically case series will have no comparator or control group.
Some have no comparators (C), some have brownout reset (BOR), and the ADC varies from slope to SARs.
Drugs tested in single arm trials or drugs with multiple doses evaluated without separate comparators were classified as having no comparators.
Since this is the first production-grade tool for PTD and ITD detection in RNA-seq data, we have no comparators for its performance for these event types.
For EM13309 (anti-αvβ8), we had no appropriate comparator antibody available, but the biochemical, cytometric, and IHC patterns were unequivocal.
However, as in both the studies IDegAsp was titrated using the same algorithm as the comparator, this finding has no clinical implications in these studies.
The present study does have limitations; we have no control or comparator group to allow us to determine the effect of our use of this graft material on the results observed.
